More reasons not to use RGemOx if you have access to Mosun, Glofit and/or pola: now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...

Excellent work Toby Eyre et al on this comprehensive @myesmo.bsky.social Huge body of work and practical guidance for the staging and management of the breadth of these conditions #lymphoma #guidelines #lymSM lnkd.in/gESZfHXY

Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL @chancheah.bsky.social #EHA2025 #lymsm #hematology www.onclive.com/view/glofita...

Is your CLL and MCL management approach aligned with the latest evidence and patient preferences? Find out more in this activity bit.ly/4nRN3r3 @medscape.com #lymphoma #medicaleducation #clinicaltrials #leukemia

It was a pleasure to catch up with @chancheah.bsky.social‬ at #EHA2025 to hear the updated Phase I results of sonrotoclax plus zanubrutinib in patients with R/R CLL/SLL.🩸 Watch the interview here: 👉 buff.ly/TYQfq4h 👈 #CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc

Fastest review I have ever been involved with - written almost entirely on the plane back from #ASH24 #lymSM Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

pleased to share this review of CD19 x CD3 bispecific TCE from our group. Kudos to my registrar Harry Hambleton #lymSM The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma www.tandfonline.com/doi/full/10....

Great to see this study of nivolumab and rituximab in follicular lymphoma just out in @bloodadvances.bsky.social ashpublications.org/bloodadvance... kudos @elizahawkes.bsky.social #lymSM

Great article about Prof John Seymour @petermaccc.bsky.social in @ash-hematology.bsky.social Clinical News sharing his love of cycling ashpublications.org/ashclinicaln... 🚴‍♂️

Great to see this published! Effect of replacing procarbazine for dacarbazine in escBEACOPP for Hodgkin treatment. Hugely beneficial effect on genotoxicity. Really no role for procarbazine in front line Hodgkin nowadays. #lymsm www.thelancet.com/journals/lan...

Neelapu: long term Zuma5 FU (Axi-cel FL) - 127 efficacy pts, R/R FL 2+ prior lines - at >5y FU, >50% alive, no further Rx - PFS at 5y approx 50% - NRM approx 15% - only 1 PD event after 4y - Apply to high risk incl POD24 Does support curative potential in FL #ASH24 #lymsm

Epco monotherapy in age >75 DLBCL #ASH24: - 45 pts, 38% age >85, all anthracycline ineligible - ORR 69%, CR 62% - 6-mo DOR 82%, PFS 73%, OS 81% - 5 fatal TEAEs (COVID, CMV, TLS), 8 pts d/c'd d/t TEAEs Seems fairly toxic; some debulking needed prior? #lymsm #gerionc

Kim: ELM2, odronextamab in RR MZL - ORR 77% (all CRs) - CRS all G1/2 and no ICANS - durable responses on the whole - ongoing trial of Len-odron v R2 Great to see active drug being investigated specifically in MZL. #ASH24 #lymsm

Kudos to all the presenters at #ASH24 for whom English is a second language. It can’t be easy, particularly answering questions.

Kirsten: results from ATALANTA study - GLPG5101 in R/R B-cell malig - 7d vein-vein, decentralised manufacture - no bridging needed - produces stem-like early memory T-cell product - low rates G3 CRS/ICANs - 54% CR DLBCL, 100% MCL, 95% FL Definitely one to watch. #ASH24 #lymsm

My ex-fellow and now colleague Dr Kat Lewis in action presenting the ALLG PACIFIC study of pembrolizumab R-CHOP in primary mediastinal B-cell lymphoma. Stop by poster 1721! #ASH24 #lymSM

Falchi: 1L subcut mosunutuzumab Follicular - 80 pts, all need Rx by GELF - Fixed duration (8 cycles if CMR; 17 if not) - ORR 96%, CRR 80% - v durable responses (FU still short) - CRS almost all low grade Will see more 1L bispecific FL trials I'm sure. #ASH24 #lymsm

Dr Hou: phase I data for CD19 x CD3 T-cell engaging antibody AZD486 in 3L+ follicular lymphoma. With double step up dosing, CRS was all grade 1, low toci use (13%). Highly active (CR rate 85%) + high rates of uMRD. The 1L study SOUNDTRACK F1 is open at SCGH #lymSM #hemeSky #ASH24

Dear @ash-hematology.bsky.social #ASH24… while most of the meeting is incredibly well organised - thank you! - sadly all of the lymphoma sessions have been in rooms which are far too small! 😕 Not the same in the overflow rooms…

Martin Dreyling presents long term update of the TRIANGLE study (European MCL network) Practice changer (if you can access 1L BTKi) fixed duration ibrutinib in 1L treatment naive mantle cell lymphoma patients leads to superior OS compared with ASCT as a consolidation strategy #lymSM #hemeSky #ASH24

Dr Aymard showing sobering outcomes for post CART mantle cell lymphoma #ASH24 bispecific best outcomes but n=7 only similar data to the US Consortium #lymSM #hemeSky

Lewis et al: ENRICH study in 1L MCL - Ibr+ritux vs R-chemo (RCHOP or R-benda) - 400 pts, >60y -PFS: prolonged with IR - Largely driven by benefit over R-CHOP - Blastoid did not benefit from IR - OS the same - 22% cardiac AEs with IR 1st trial to show benefit chemo-free in 1L MCL. #ASH24 #lymsm

The best way to kick off #ASH24 - on a road bike! www.strava.com/activities/1... #strava #lymSM #hemeSKY

observation of the morning: most people wandering San Diego hotels looking for coffee at 4am are international #ASH24 attendees 😁

Kudos to my fellow Brian Grainger on this review just out in Haematologica We highlight new and emerging data for novel therapeutics in post BTK inhibitor mantle cell lymphoma #lymSM Open access link haematologica.org/article/view...

Best thing about the (long) flight to #ASH24 is reviewing all the manuscripts my mentees send me before I get on the plane! Always a pleasure to see academic skills in development #lymSM @ash-hematology.bsky.social

Delighted to be at #ASH24 in sunny San Diego. Looking forward to seeing friends and colleagues in the #lymSM world!